Philips showcases clinical data and solutions designed to deliver better cardiac care with greater efficiency at TCT 2022 - Seite 2
Philips’ latest technology advancements in diagnostic, interventional and monitoring solutions at TCT 2022 include:
-
Philips 3D Intracardiac Echocardiography Catheter – VeriSight Pro: Used with Philips’ premium cardiology ultrasound systems EPIQ CVx and CVxi, the VeriSight Pro offers
superior 2D and 3D live-image guidance for a wide range of procedures in structural heart disease and electrophysiology.
-
Simplifying coronary and peripheral atherectomy and lead extraction procedures with Philips Laser System – Nexcimer: The only system compatible with catheters that have Level I clinical data for ISR
atherectomy and that can also support lead extraction procedures (the removal of pacemaker or defibrillator leads around the heart) [3,4].
- Philips live fluoroscopy-echo fusion imaging – EchoNavigator 4.0: Used with the Philips Image Guided Therapy System - Azurion - and Philips’ premium cardiology ultrasound system – EPIQ CVxi, the new EchoNavigator Release 4.0 empowers heart teams with greater control of live fusion imaging plus new anatomical modeling and transeptal guidance during minimally-invasive structural heart disease procedures.
Published clinical data presented at TCT 2022
IVUS consensus and large-scale, real-world data summary: On Saturday, September 17, at 11:30am ET in the Philips Engagement Hub, Eric A. Secemsky, MD, Interventional
Cardiologist at Beth Israel Deaconess Medical Center and Assistant Professor of Medicine at Harvard Medical School in Boston, MA, will review two critically important data sets released in late
2021 that highlight the importance of IVUS for both arterial and venous procedures, including the new consensus document from 30 global vascular experts, which recommends routine use of IVUS as a
preferred imaging modality in all phases in many peripheral vascular disease (PVD) procedures, published in the August 2022 issue of the Journal of the American College of Cardiology:
Cardiovascular Interventions as “Appropriate Use of Intravascular Ultrasound During Arterial and Venous Lower Extremity Interventions.”
Lesen Sie auch
New study validates ambulatory monitoring as a valuable, cost-neutral tool
Many patients with severe symptomatic aortic stenosis (SAS) are treated with a transcatheter aortic valve replacement (TAVR) – a minimally invasive procedure that replaces a diseased aortic valve
with a prosthetic valve. As an alternative to open-heart aortic valve replacement surgery, TAVR treatment offers several benefits for symptomatic SAS patients, including reduced length of hospital
stay and an increased likelihood of home discharge [5].